Common use of Improvements in the Manufacture of Compounds Clause in Contracts

Improvements in the Manufacture of Compounds. During the Term, Ambrx shall disclose to BMS through the JRC (or if the JRC is not constituted, through the Alliance Managers) any improvements made or developed with respect to the prokaryotic expression and/or production of proteins made using the Ambrx ReCODE Technology, including any PEG conjugates thereof, Controlled by Ambrx (“Improvements”). Such Improvements may include, for example, improvements (i) to the tRNA and aminoacyl tRNA synthetases used in such expression and production, (ii) in the non-naturally occurring amino acid(s) incorporated into such proteins, (iii) in fermentation methods, (iv) in the expression vector and/or hosts strain for expression and production of such proteins and (v) in the PEG conjugation chemistry and methods. Upon request by BMS, Ambrx will provide BMS with the Ambrx Know-How and/or Ambrx Materials in Ambrx’s or its Affiliate’s possession and Control that are necessary or reasonably useful for BMS or its Third Party manufacturer to use such Improvements in the manufacture of Compounds.

Improvements in the Manufacture of Compounds. During the Term, Ambrx shall disclose to BMS (through the JRC (or if still constituted or, if the JRC is not constituted, through the Alliance Managers) any improvements made or developed with respect to the prokaryotic expression and/or production of proteins made using the Ambrx ReCODE Technology, including any PEG conjugates thereof, Controlled by Ambrx (“Improvements”). Such Improvements may include, for example, improvements (i) to the tRNA and aminoacyl tRNA synthetases used in such expression and production, (ii) in the non-naturally occurring amino acid(s) incorporated into such proteins, (iii) in fermentation methods, (iv) in the expression vector and/or hosts strain for expression and production of such proteins and (v) in the PEG conjugation chemistry and methods. Upon request by BMS, Ambrx will provide BMS with the Ambrx Know-How and/or Ambrx Materials in Ambrx’s or its Affiliate’s possession and Control that are necessary or reasonably useful for BMS or its Third Party manufacturer to use such Improvements in the manufacture of Compounds.

Improvements in the Manufacture of Compounds. During the Term, Ambrx shall disclose to BMS through the JRC (or if the JRC is not constituted, through the Alliance Managers) any improvements made or developed with respect to the prokaryotic expression and/or production of proteins made using the Ambrx ReCODE Technology, including any PEG conjugates thereof, ReCODE/EuCODE Technology that are Controlled by Ambrx (“Improvements”). Such Improvements may include, for example, improvements (i) to the tRNA and aminoacyl amino acyl tRNA synthetases used in such expression and production, (ii) in the non-naturally occurring amino acid(s) incorporated into such proteins, (iii) in fermentation methods, methods and (iv) in the expression vector and/or hosts strain host strains for expression and production of such proteins and (v) in the PEG conjugation chemistry and methodsproteins. Upon request by BMS, Ambrx will provide BMS with the Ambrx Know-How and/or Ambrx Materials in Ambrx’s or its Affiliate’s possession and Control that are required or necessary or reasonably useful for BMS (or its a Third Party manufacturer designated by BMS in accordance with Section 6.4) to use such Improvements in the manufacture of Compounds.